ВОЗМОЖНОСТИ КОМБИНИРОВАННОЙ АНТИГИПЕРТЕНЗИВНОЙ ТЕРАПИИ ПРИ СОЧЕТАНИИ АРТЕРИАЛЬНОЙ ГИПЕРТЕНЗИИ И ИШЕМИЧЕСКОЙ БОЛЕЗНИ СЕРДЦА
2013
The leading positions in the treatment of patients with arterial hypertension (AH) and coronary heart disease (CHD) are held by angiotensin-converting enzyme (ACE) inhibitors and beta-adrenoblockers (BAB), which have demonstrated their effectiveness in terms of improved patients’ survival. In patients with AH and CHD, the rational, pathogenetic pharmacotherapy using a combination of an ACE inhibitor zofenopril and a highly cardio-selective and vasodilating BAB nebivolol demonstrates antihypertensive and antiischemic action, decreases the risk of potential adverse cardio-metabolic effects, reduces the severity of endothelial dysfunction, and, consequently, improves quality of life.
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
0
References
0
Citations
NaN
KQI